Xie Y, Lv S, Luo S, Chen Y, Du M, Xu Y
Front Immunol. 2024; 15:1347311.
PMID: 39021569
PMC: 11251897.
DOI: 10.3389/fimmu.2024.1347311.
Costaguta G, Girard C, Groleau V, Grzywacz K, Dirks M, Deslandres C
J Can Assoc Gastroenterol. 2024; 7(2):196-203.
PMID: 38596797
PMC: 10999772.
DOI: 10.1093/jcag/gwad042.
Chebbi P, Shobha V, Rao V, Haridas V, Janardana R, Pinto B
BMC Rheumatol. 2023; 7(1):22.
PMID: 37496101
PMC: 10369741.
DOI: 10.1186/s41927-023-00345-8.
Maynard N, Armstrong A
Curr Dermatol Rep. 2023; 12(2):45-55.
PMID: 37304177
PMC: 10068706.
DOI: 10.1007/s13671-023-00385-w.
Wang Y, Li P, Lavrijsen M, Rottier R, den Hoed C, Bruno M
United European Gastroenterol J. 2023; 11(5):431-447.
PMID: 37226653
PMC: 10256998.
DOI: 10.1002/ueg2.12417.
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.
Xue Y, Mei H, Chen Y, Griffin J, Liu Q, Weisberg E
MedComm (2020). 2023; 4(3):e254.
PMID: 37193304
PMC: 10183156.
DOI: 10.1002/mco2.254.
Tofacitinib to Treat Severe Acute Refractory Colitis in a Teenager: Case Report and Review of the Literature.
Girard C, Dirks M, Deslandres C
JPGN Rep. 2023; 3(3):e241.
PMID: 37168636
PMC: 10158282.
DOI: 10.1097/PG9.0000000000000241.
Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.
Jain N, Tailang M, Jain H, Chandrasekaran B, Sahoo B, Subramanian A
Front Pharmacol. 2023; 14:1135145.
PMID: 37021053
PMC: 10067607.
DOI: 10.3389/fphar.2023.1135145.
SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study.
Geldof J, Truyens M, Sabino J, Ferrante M, Lambert J, Lapeere H
Front Immunol. 2023; 14:1126351.
PMID: 36936974
PMC: 10014825.
DOI: 10.3389/fimmu.2023.1126351.
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
Nunez P, Quera R, Yarur A
Drugs. 2023; 83(4):299-314.
PMID: 36913180
PMC: 10010235.
DOI: 10.1007/s40265-023-01840-5.
COVID-19 and Inflammatory Bowel Disease.
Summa K, Hanauer S
Gastroenterol Clin North Am. 2023; 52(1):103-113.
PMID: 36813419
PMC: 9618438.
DOI: 10.1016/j.gtc.2022.10.005.
Risk of COVID-19 Infection After Full Immunization in Patients With Inflammatory Bowel Disease on Treatment: A Research Network Analysis.
Tomanguillo J, Searls L, Annie F, Kemper S, Naravadi V
Cureus. 2023; 15(1):e34004.
PMID: 36811056
PMC: 9939048.
DOI: 10.7759/cureus.34004.
Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis.
Abdulla M, Mohammed N, AlQamish J, Mosli M
Sci Rep. 2022; 12(1):21333.
PMID: 36494448
PMC: 9734125.
DOI: 10.1038/s41598-022-25429-2.
COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy.
Khaledi M, Sameni F, Yahyazade S, Radandish M, Owlia P, Bagheri N
Front Med (Lausanne). 2022; 9:961027.
PMID: 36111104
PMC: 9469902.
DOI: 10.3389/fmed.2022.961027.
Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.
Esposito S, Caminiti C, Giordano R, Argentiero A, Ramundo G, Principi N
Front Immunol. 2022; 13:933774.
PMID: 35812420
PMC: 9260046.
DOI: 10.3389/fimmu.2022.933774.
The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic.
Kamath C, Brenner E
Curr Res Pharmacol Drug Discov. 2022; 3:100101.
PMID: 35496814
PMC: 9040409.
DOI: 10.1016/j.crphar.2022.100101.
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
Lin S, Lau L, Chanchlani N, Kennedy N, Ng S
Gut. 2022; 71(7):1426-1439.
PMID: 35477864
PMC: 9185820.
DOI: 10.1136/gutjnl-2021-326784.
Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.
Alrashed F, Alasfour H, Shehab M
JGH Open. 2022; 6(4):241-250.
PMID: 35475207
PMC: 9021715.
DOI: 10.1002/jgh3.12728.
Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.
Liu E, Aslam N, Nigam G, Limdi J
Drugs Context. 2022; 11.
PMID: 35462642
PMC: 9007061.
DOI: 10.7573/dic.2021-11-4.
Impact of COVID-19 on Healthcare Resource Utilisation Among Patients with Inflammatory Bowel Disease in the USA.
Ungaro R, Chou B, Mo J, Ursos L, Twardowski R, Candela N
J Crohns Colitis. 2022; 16(9):1405-1414.
PMID: 35396598
PMC: 9047243.
DOI: 10.1093/ecco-jcc/jjac056.
